Evaluation of Phlebitis Attribute to Chemotherapy in Colorectal Cancer Patients of Our Institution
| Autor: | Mayumi Oda, Mahiru Fukuda, Ai Mogi, Yuichi Yamashita, Yasushi Takamatsu, Tomoka Kuboda, Hideki Kakimoto, Yoichiro Yoshida, Megumi Nishida, Kazuo Tamura |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Common Terminology Criteria for Adverse Events Hematology Chemotherapy regimen Fosaprepitant Surgery Irinotecan Regimen medicine.anatomical_structure Internal medicine medicine Vein business Aprepitant medicine.drug |
| Zdroj: | Annals of Oncology. 25:v67 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdu435.98 |
| Popis: | Background: Introduction of oral fluoropyrimidine eliminates the need for central vein catheter placement in patients who receive fluoropyrimidine-containing regimen. However, patients some time experience phlebitis attribute to administration of agents other than fluoropyrimidine through peripheral vein. Methods: The incidence of phlebitis was investigated in 80 patients with colorectal cancer who were treated with oral fluoropyrimidine plus oxialiplatin or irinotecan regimens through peripheral vein between January 2013 and December 2013. All data were retrospectively collected from the electronic medical record system. Results: The phlebitis was observed in 13 of 80 patients (16.3%) including induration in 12, redness in 4 and pain in 3. All phlebitis cases were defined as grade 1 by Common Terminology Criteria for Adverse Events version 4.0. None of them postponed the treatment due to phlebitis. The phlebitis improved in 11 of 13 patients. Fosaprepitant Meglumine was used in higher number of patient who developed phlebitis in comparison to these who did not (92.3% vs. 52.2%, p Conclusions: The significant number of patients development phlebitis when oral fluoropyrimidine plus oxialiplatin or irinotecan was given through peripheral vein, but all of them were mild. Intravenous administration of fosaprepitant might be involved in the development of phlebitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|